LT2244722T - Mikrobinių infekcijų gydymas - Google Patents

Mikrobinių infekcijų gydymas

Info

Publication number
LT2244722T
LT2244722T LTEP09705327.6T LT09705327T LT2244722T LT 2244722 T LT2244722 T LT 2244722T LT 09705327 T LT09705327 T LT 09705327T LT 2244722 T LT2244722 T LT 2244722T
Authority
LT
Lithuania
Prior art keywords
treatment
microbial infections
infections
microbial
Prior art date
Application number
LTEP09705327.6T
Other languages
English (en)
Inventor
Timothy Foster
Judy Higgins
Elisabet Josefsson
Joan Geoghegan
Andrej Tarkowski
Original Assignee
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2244722(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0801768.3A external-priority patent/GB0801768D0/en
Application filed by The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of filed Critical The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of
Publication of LT2244722T publication Critical patent/LT2244722T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP09705327.6T 2008-01-31 2009-01-29 Mikrobinių infekcijų gydymas LT2244722T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0801768.3A GB0801768D0 (en) 2008-01-31 2008-01-31 Treatment of microbial infections
IE20080070 2008-01-31
PCT/EP2009/051033 WO2009095453A1 (en) 2008-01-31 2009-01-29 Treatment of microbial infections

Publications (1)

Publication Number Publication Date
LT2244722T true LT2244722T (lt) 2016-10-25

Family

ID=40512496

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP09705327.6T LT2244722T (lt) 2008-01-31 2009-01-29 Mikrobinių infekcijų gydymas

Country Status (22)

Country Link
US (3) US20110150918A1 (lt)
EP (2) EP3117832B1 (lt)
JP (1) JP5709527B2 (lt)
KR (1) KR101739048B1 (lt)
CN (1) CN101983067B (lt)
AU (1) AU2009209598B2 (lt)
BR (1) BRPI0906997A2 (lt)
CA (1) CA2713241C (lt)
CY (1) CY1118153T1 (lt)
DK (1) DK2244722T3 (lt)
EA (1) EA019516B1 (lt)
ES (2) ES2599953T3 (lt)
HR (1) HRP20161305T1 (lt)
HU (1) HUE031614T2 (lt)
LT (1) LT2244722T (lt)
MX (1) MX2010008423A (lt)
PL (1) PL2244722T3 (lt)
PT (1) PT2244722T (lt)
SG (1) SG188102A1 (lt)
SI (1) SI2244722T1 (lt)
WO (1) WO2009095453A1 (lt)
ZA (1) ZA201005798B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996231A4 (en) * 2006-02-22 2010-09-15 Texas A & M Univ Sys ANTIBODIES WITH STRONG EXPRESSED PUTATIVE ANTIGEN DETECTION OF CA-MRSA AND METHOD OF USE
SG188102A1 (en) 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
JP6192294B2 (ja) 2009-07-15 2017-09-06 エーアイエムエム セラピューティクス ベー．フェー． グラム陽性菌特異的結合化合物
CA2768485C (en) 2009-07-16 2018-12-04 Timothy Foster Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011045573A2 (en) 2009-10-15 2011-04-21 University Court Of The University Of Edinburgh Staphylococcal antigens
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
WO2013159021A1 (en) * 2012-04-20 2013-10-24 The Texas A&M University System Engineered collagen binding mscramm with enhanced affinity for collagen
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
AU2019258504B2 (en) * 2018-04-24 2020-03-12 Fibriant B.V. Therapeutic uses of fibrinogen gamma prime variants
US12502424B2 (en) 2023-05-05 2025-12-23 Sanofi Pasteur Inc. Compositions for use in treatment of acne

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
AU4810600A (en) * 1999-04-28 2000-11-10 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Method of inhibiting leukocyte adhesion to fibrinogen
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
JP2008502363A (ja) 2004-05-21 2008-01-31 ワイス Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓの改変型フィブロネクチン結合タンパク質
SG188102A1 (en) 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections

Also Published As

Publication number Publication date
US20110150918A1 (en) 2011-06-23
CA2713241A1 (en) 2009-08-06
WO2009095453A1 (en) 2009-08-06
MX2010008423A (es) 2010-09-22
KR101739048B1 (ko) 2017-05-23
HUE031614T2 (en) 2017-07-28
EP3117832B1 (en) 2023-09-27
US20150232518A1 (en) 2015-08-20
PT2244722T (pt) 2016-11-04
CN101983067A (zh) 2011-03-02
EP2244722B1 (en) 2016-07-27
DK2244722T3 (en) 2016-11-14
EA201001212A8 (ru) 2014-03-31
US11512118B2 (en) 2022-11-29
EA201001212A1 (ru) 2011-02-28
PL2244722T3 (pl) 2017-04-28
EP2244722A1 (en) 2010-11-03
HRP20161305T1 (hr) 2017-01-27
AU2009209598A1 (en) 2009-08-06
EA019516B1 (ru) 2014-04-30
BRPI0906997A2 (pt) 2015-07-07
CN101983067B (zh) 2017-07-11
ES2960604T3 (es) 2024-03-05
AU2009209598B2 (en) 2012-07-26
SI2244722T1 (sl) 2017-01-31
CY1118153T1 (el) 2017-06-28
EP3117832C0 (en) 2023-09-27
ES2599953T3 (es) 2017-02-06
JP5709527B2 (ja) 2015-04-30
JP2011510952A (ja) 2011-04-07
CA2713241C (en) 2022-10-04
US9637525B2 (en) 2017-05-02
EP3117832A1 (en) 2017-01-18
SG188102A1 (en) 2013-03-28
US20170202943A1 (en) 2017-07-20
KR20110000624A (ko) 2011-01-04
ZA201005798B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
ZA201005798B (en) Treatment of microbial infections
ZA201006648B (en) Methods of treatment
PL2326287T3 (pl) Modułowe urządzenie rozprzestrzeniające do leczenia protetycznych zakażeń stawów
ZA200906126B (en) Use of IL-23 antigonists for treatment of infection
GB0818074D0 (en) Treatment of biofilms
GB0802116D0 (en) Treatment
PL2696890T3 (pl) Leczenie infekcji drobnoustrojowych
EP2257569A4 (en) METHOD OF TREATMENT USING ANTIMICROBIAL COMPOSITION
DK2473482T3 (en) Methods of treating orthomyxoviral infections
ZA201100616B (en) Treatment of antibiotic-resistant bacteria infection
GB0811992D0 (en) Treatment
PT2424559T (pt) Métodos de tratamento de infeções bacterianas utilizando oritavancina
GB0513096D0 (en) Treatment of microbial infections
EP2417258A4 (en) BACTERIOPHAGE COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
ZA201204249B (en) Treatment of microbial infections
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
PH12012500528A1 (en) Compositions and methods for treating bacterial infections using caftaroline
ZA201100468B (en) The treatment of helminthic infections
GB0805912D0 (en) Treatment
GB0801768D0 (en) Treatment of microbial infections
GB0807781D0 (en) Treatment of bacterial infection
GB0711704D0 (en) Treatment of staphylococcal infections
AU2009900969A0 (en) Treatment of infection
GB0817437D0 (en) Compounds for the treatment of flaviviral infections